Golnerminogene pradenovec

N/A

Report date: 2023/10/26 16:19:31

Base Information

Drug NameGolnerminogene pradenovec
Drug Alias Name普-戈米诺近golnerminogenum pradenovecumTNF-α gene therapy普拉戈基普拉敏基 +[8] 
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vector > Ad5 vectorBiologics > Oncolytic virus
Mechanisms of ActionGene transferenceTumor necrosis factor α stimulants
TargetsTumor necrosis factor α
Therapy Area/IndicationsHead and Neck NeoplasmsPancreatic NeoplasmsRectal Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAsahi Kasei Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGenvec LlcH Lee Moffitt Cancer Center & Research InstituteNational Cancer Institute +[4] 
Active IndicationsN/A
Inactive IndicationsHead and Neck NeoplasmsPancreatic NeoplasmsRectal Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A